( July 7, 2026, 9:42 AM EDT) -- PHILADELPHIA — The Pennsylvania federal judge overseeing the multidistrict litigation of cases alleging that the use of glucagon-like peptide-I receptor agonist XE "glucagon-like
peptide-I receptor agonist" (GLP-1 RA) medications caused permanent vision loss has granted the drug manufacturers’ “request for early discovery and motion practice as to the cross cutting issues of general causation and preemption/warning adequacy.”...